









- [19] VOLANTE M, TOTA D, GIORCELLI J, BOLLITO E, NAPOLI F, VATRANO S, et al. Androgen deprivation modulates gene expression profile along prostate cancer progression[J]. *Hum Pathol*, 2016, 56: 81-88.
- [20] MOUNIR Z, LIN F, LIN V G, KORN J M, YU Y, VALDEZ R, et al. *TMPRSS2:ERG* blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation[J]. *Oncogene*, 2015, 34: 3815-3825.
- [21] JUNG S H, SHIN S, KIM M S, BAEK I P, LEE J Y, LEE S H, et al. Genetic progression of high grade prostatic intraepithelial neoplasia to prostate cancer[J]. *Eur Urol*, 2016, 69: 823-830.
- [22] PARK J W, LEE J K, WITTE O N, HUANG J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate[J]. *Mod Pathol*, 2017, 30: 1262-1272.
- [23] MIRÓSEVICH J, GAO N, GUPTA A, SHAPPELL S B, JOVE R, MÁTUSIK R J. Expression and role of Foxa proteins in prostate cancer[J]. *Prostate*, 2006, 66: 1013-1028.
- [24] QI J, NAKAYAMA K, CARDIFF R D, BOROWSKY A D, KAUL K, WILLIAMS R, et al. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors[J]. *Cancer Cell*, 2010, 18: 23-38.
- [25] GUPTA A, YU X, CASE T, PAUL M, SHEN M M, KAESTNER K H, et al. Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of *Foxa2*[J]. *Prostate*, 2013, 73: 582-589.
- [26] KALLIO H M L, HIETA R, LATONEN L, BROFELDT A, ANNALA M, KIVINUMMI K, et al. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases[J]. *Br J Cancer*, 2018, 119: 347-356.
- [27] MAGANI F, PEACOCK S O, RICE M A, MARTINEZ M J, GREENE A M, MAGANI P S, et al. Targeting *AR* variant-coactivator interactions to exploit prostate cancer vulnerabilities[J]. *Mol Cancer Res*, 2017, 15: 1469-1480.
- [28] LAPUK A V, WU C, WYATT A W, MCPHERSON A, MCCONEGHY B J, BRAHMBHATT S, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer[J]. *J Pathol*, 2012, 227: 286-297.
- [29] ZHU Y, LIU C, CUI Y, NADIMINTY N, LOU W, GAO A C. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST)[J]. *Prostate*, 2014, 74: 1086-1094.
- [30] LIANG H, STUDACH L, HULLINGER R L, XIE J, ANDRISANI O M. Down-regulation of RE-1 silencing transcription factor (REST) in advanced prostate cancer by hypoxia-induced miR-106b~25[J]. *Exp Cell Res*, 2014, 320: 188-199.
- [31] QUESNEL-VALLIÈRES M, IRIMIA M, CORDES S P, BLENCOWE B J. Essential roles for the splicing regulator nSR100/SRRM4 during nervous system development[J]. *Genes Dev*, 2015, 29: 746-759.
- [32] ZHANG X, COLEMAN I M, BROWN L G, TRUE L D, KOLLATH L, LUCAS J M, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer[J]. *Clin Cancer Res*, 2015, 21: 4698-4708.
- [33] CALCINOTTO A, SPATARO C, ZAGATO E, DI MITRI D, GIL V, CRESPO M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer[J]. *Nature*, 2018, 559: 363-369.
- [34] SIEGALL C B, SCHWAB G, NORDAN R P, FITZGERALD D J, PASTAN I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells[J]. *Cancer Res*, 1990, 50: 7786-7788.
- [35] WANG Q, HORIATIS D, PINSKI J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation[J]. *Int J Cancer*, 2004, 111: 508-513.
- [36] WANG C, PENG G, HUANG H, LIU F, KONG D P, DONG K Q, et al. Blocking the feedback loop between neuroendocrine differentiation and macrophages improves the therapeutic effects of enzalutamide (MDV3100) on prostate cancer[J]. *Clin Cancer Res*, 2018, 24: 708-723.
- [37] GE D, GAO A C, ZHANG Q, LIU S, XUE Y, YOU Z. LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling[J]. *Prostate*, 2012, 72: 1306-1316.